Jardé Thierry, Kass Lisa, Staples Margaret, Lescesen Helen, Carne Peter, Oliva Karen, McMurrick Paul J, Abud Helen E
Department of Anatomy and Developmental Biology, Monash University, Wellington Rd., Clayton, Victoria, Australia; Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Department of Anatomy and Developmental Biology, Monash University, Wellington Rd., Clayton, Victoria, Australia.
PLoS One. 2015 Sep 14;10(9):e0138336. doi: 10.1371/journal.pone.0138336. eCollection 2015.
Several studies have suggested ERBB3/HER3 may be a useful prognostic marker for colorectal cancer. Tumours with an intestinal stem cell signature have also been shown to be more aggressive. Here, we investigate whether ERBB3 is associated with intestinal stem cell markers in colorectal cancer and if cancer stem cells within tumours are marked by expression of ERBB3. Expression of ERBB3 and intestinal stem cell markers (LGR5, EPHB2, CD44s and CD44v6) was assessed by qRT-PCR in primary colorectal tumours (stages 0 to IV) and matched normal tissues from 53 patients. The localisation of ERBB3, EPHB2 and KI-67 within tumours was investigated using co-immunofluorescence. Expression of ERBB3 and intestinal stem cell markers were significantly elevated in adenomas and colorectal tumours compared to normal tissue. Positive correlations were found between ERBB3 and intestinal stem cell markers. However, co-immunofluorescence analysis showed that ERBB3 and EPHB2 marked specific cell populations that were mutually exclusive within tumours with distinct proliferative potentials, the majority of ERBB3+ve cells being non-proliferative. This pattern resembles cellular organisation within normal colonic epithelium where EPHB2 labelled proliferative cells reside at the crypt base and ERBB3+ve cells mark differentiated cells at the top of crypts. Our results show that ERBB3 and intestinal stem cell markers correlate in colorectal cancers. ERBB3 localises to differentiated cell populations within tumours that are non-proliferative and distinct from cancer stem cells. These data support the concept that tumours contain discrete stem, proliferative and differentiation compartments similar to that present in normal crypts.
多项研究表明,ERBB3/HER3可能是结直肠癌有用的预后标志物。具有肠道干细胞特征的肿瘤也显示出更具侵袭性。在此,我们研究ERBB3在结直肠癌中是否与肠道干细胞标志物相关,以及肿瘤内的癌症干细胞是否以ERBB3的表达为标志。通过qRT-PCR评估了53例患者原发性结直肠癌(0至IV期)及配对正常组织中ERBB3和肠道干细胞标志物(LGR5、EPHB2、CD44s和CD44v6)的表达。使用共免疫荧光研究了ERBB3、EPHB2和KI-67在肿瘤内的定位。与正常组织相比,腺瘤和结直肠癌中ERBB3和肠道干细胞标志物的表达显著升高。ERBB3与肠道干细胞标志物之间存在正相关。然而,共免疫荧光分析显示,ERBB3和EPHB2标记了肿瘤内具有不同增殖潜能的相互排斥的特定细胞群,大多数ERBB3阳性细胞是非增殖性的。这种模式类似于正常结肠上皮内的细胞组织,其中EPHB2标记的增殖细胞位于隐窝底部,ERBB3阳性细胞标记隐窝顶部的分化细胞。我们的结果表明,ERBB3与结直肠癌中的肠道干细胞标志物相关。ERBB3定位于肿瘤内非增殖性且与癌症干细胞不同的分化细胞群。这些数据支持肿瘤包含与正常隐窝中类似的离散干细胞、增殖和分化区室的概念。